{"id":"https://openalex.org/W3067119682","doi":"https://doi.org/10.1111/bjh.17029","title":"Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin","display_name":"Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin","publication_year":2020,"publication_date":"2020-08-17","ids":{"openalex":"https://openalex.org/W3067119682","doi":"https://doi.org/10.1111/bjh.17029","mag":"3067119682","pmid":"https://pubmed.ncbi.nlm.nih.gov/32805058"},"language":"en","primary_location":{"id":"doi:10.1111/bjh.17029","doi":"https://doi.org/10.1111/bjh.17029","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bjh.17029","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.17029","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.17029","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071844603","display_name":"Ryan Daniel Cassaday","orcid":"https://orcid.org/0000-0002-3424-2425","observed_orcids":["https://orcid.org/0000-0002-3424-2425"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ryan D. Cassaday","raw_affiliation_strings":["University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0002-3424-2425","affiliations":[{"raw_affiliation_string":"University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111693401","display_name":"David Ian Marks","orcid":"https://orcid.org/0000-0003-3821-6352","observed_orcids":["https://orcid.org/0000-0003-3821-6352"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David I. Marks","raw_affiliation_strings":["University Hospitals Bristol, Bristol, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospitals Bristol, Bristol, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082924494","display_name":"Daniel J. DeAngelo","orcid":"https://orcid.org/0000-0001-7865-2306","observed_orcids":["https://orcid.org/0000-0001-7865-2306"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J. DeAngelo","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049385583","display_name":"Elias Joseph Jabbour","orcid":"https://orcid.org/0000-0003-4465-6119","observed_orcids":["https://orcid.org/0000-0003-4465-6119"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elias J. Jabbour","raw_affiliation_strings":["University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082944296","display_name":"Anjali S. Advani","orcid":"https://orcid.org/0000-0003-0015-5902","observed_orcids":["https://orcid.org/0000-0003-0015-5902"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anjali S. Advani","raw_affiliation_strings":["Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA"],"raw_orcid":"https://orcid.org/0000-0003-0015-5902","affiliations":[{"raw_affiliation_string":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006104041","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0002-2481-7504","observed_orcids":["https://orcid.org/0000-0002-2481-7504"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]},{"id":"https://openalex.org/I4390039238","display_name":"UC Irvine Chao Family Comprehensive Cancer Center","ror":"https://ror.org/05gzqy922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I204250578","https://openalex.org/I4390039238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan O\u2019Brien","raw_affiliation_strings":["Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, USA","institution_ids":["https://openalex.org/I204250578","https://openalex.org/I4390039238"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115695385","display_name":"Tao Wang","orcid":"https://orcid.org/0009-0003-1825-0163","observed_orcids":["https://orcid.org/0009-0003-1825-0163","https://orcid.org/0000-0002-5910-8775"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tao Wang","raw_affiliation_strings":["Pfizer Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Cambridge, MA, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081736171","display_name":"Alexander Neuhof","orcid":"https://orcid.org/0000-0002-7926-2593","observed_orcids":["https://orcid.org/0000-0002-7926-2593"]},"institutions":[{"id":"https://openalex.org/I4210100293","display_name":"Pfizer (Germany)","ror":"https://ror.org/00m8w3m39","country_code":"DE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210100293"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Alexander Neuhof","raw_affiliation_strings":["Pfizer Pharma GmbH, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Pharma GmbH, Berlin, Germany","institution_ids":["https://openalex.org/I4210100293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009581524","display_name":"Erik R. Vandendries","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erik Vandendries","raw_affiliation_strings":["Pfizer Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Cambridge, MA, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop M. Kantarjian","raw_affiliation_strings":["University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005939966","display_name":"Wendy Stock","orcid":"https://orcid.org/0000-0002-8349-9200","observed_orcids":["https://orcid.org/0000-0002-8349-9200"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wendy Stock","raw_affiliation_strings":["University of Chicago, Chicago, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL, USA","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006288618","display_name":"Matthias Stelljes","orcid":"https://orcid.org/0000-0002-9331-5145","observed_orcids":["https://orcid.org/0000-0002-9331-5145"]},"institutions":[{"id":"https://openalex.org/I4210103666","display_name":"University Hospital M\u00fcnster","ror":"https://ror.org/01856cw59","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210103666"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Matthias Stelljes","raw_affiliation_strings":["Universit\u00e4tsklinikum M\u00fcnster M\u00fcnster Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e4tsklinikum M\u00fcnster M\u00fcnster Germany","institution_ids":["https://openalex.org/I4210103666"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5071844603"],"corresponding_institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":null,"fwci":0.6665,"has_fulltext":true,"cited_by_count":10,"citation_normalized_percentile":{"value":0.69913087,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"191","issue":"3","first_page":"e77","last_page":"e81"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/inotuzumab-ozogamicin","display_name":"inotuzumab ozogamicin","score":0.9800000190734863},{"id":"https://openalex.org/keywords/treatment-cycles","display_name":"treatment cycles","score":0.7850000262260437},{"id":"https://openalex.org/keywords/treatment-outcomes","display_name":"treatment outcomes","score":0.4729999899864197}],"concepts":[{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.7146990299224854},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.708281934261322},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.49983978271484375},{"id":"https://openalex.org/C2781107101","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Acute lymphocytic leukemia","level":4,"score":0.4322604537010193},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42665189504623413},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3849360942840576},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34369122982025146},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.19452014565467834},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/bjh.17029","doi":"https://doi.org/10.1111/bjh.17029","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bjh.17029","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.17029","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:32805058","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32805058","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Letter"}],"best_oa_location":{"id":"doi:10.1111/bjh.17029","doi":"https://doi.org/10.1111/bjh.17029","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bjh.17029","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.17029","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9476000070571899,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3067119682.pdf","grobid_xml":"https://content.openalex.org/works/W3067119682.grobid-xml"},"referenced_works_count":8,"referenced_works":["https://openalex.org/W2038981426","https://openalex.org/W2057680307","https://openalex.org/W2113426218","https://openalex.org/W2419639370","https://openalex.org/W2730231599","https://openalex.org/W2782994300","https://openalex.org/W2931981435","https://openalex.org/W2942381021"],"related_works":["https://openalex.org/W3101353354","https://openalex.org/W2951685357","https://openalex.org/W2971026936","https://openalex.org/W2972590146","https://openalex.org/W4402785626","https://openalex.org/W4409381018","https://openalex.org/W2419639370","https://openalex.org/W7010623614","https://openalex.org/W2971296434","https://openalex.org/W4405050589"],"abstract_inverted_index":{"Impact":[0],"of":[1,3,7],"number":[2],"cycles":[4],"on":[5],"outcomes":[6],"patients":[8],"with":[9,17],"relapsed":[10],"or":[11],"refractory":[12],"acute":[13],"lymphoblastic":[14],"leukaemia":[15],"treated":[16],"inotuzumab":[18],"ozogamicin":[19]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-08-24T00:00:00"}